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Abstract
Background: Proarrhythmia assessment is one of the major concerns for regulatory bodies and pharmaceutical
industry. ICH guidelines recommending preclinical tests have been established in attempt to eliminate the risk of
drug-induced arrhythmias. However, in the clinic, arrhythmia occurrence is determined not only by the inherent
property of a drug to block ion currents and disturb electrophysiological activity of cardiac myocytes, but also by
many other factors modifying individual risk of QT prolongation and subsequent proarrhythmia propensity. One of
those is drug-drug interactions. Since polypharmacy is a common practice in clinical settings, it can be anticipated
that there is a relatively high risk that the patient will receive at least two drugs mutually modifying their proarrhythmic
potential and resulting either in triggering the occurrence or mitigating the clinical symptoms. The mechanism can be
observed either directly at the pharmacodynamic level by competing for the molecular targets, or indirectly by modifying
the physiological parameters, or at the pharmacokinetic level by alteration of the active concentration of the victim drug.
Methods: This publication provides an overview of published clinical studies on pharmacokinetic and/or
pharmacodynamic drug-drug interactions in humans and their electrophysiological consequences (QT interval
modification). Databases of PubMed and Scopus were searched and combinations of the following keywords
were used for Title, Abstract and Keywords fields: interaction, coadministration, combination, DDI and electrocardiographic,
QTc interval, ECG. Only human studies were included. Over 4500 publications were retrieved and underwent preliminary
assessment to identify papers accordant with the topic of this review. 76 papers reporting results for 96 drug combinations
were found and analyzed.
Results: The results show the tremendous variability of drug-drug interaction effects, which makes one aware of
complexity of the problem, and suggests the need for assessment of an additional risk factors and careful ECG
monitoring before administration of drugs with anticipated QT prolongation.
Conclusions: DDIs can play significant roles in drugs’ cardiac safety, as evidenced by the provided examples.
Assessment of the pharmacodynamic effects of the drug interactions is more challenging as compared to the
pharmacokinetic due to the significant diversity in the endpoints which should be analyzed specifically for
various clinical effects. Nevertheless, PD components of DDIs should be accounted for as PK changes alone do
not allow to fully explain the electrophysiological effects in clinic situations.
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Background
Cardiovascular toxicity remains one of the leading causes
of early and late attrition during the drug development
process as well as a major contributor to withdrawals of
marketed drugs [1–3]. Cardiac safety concerns arise from
a variety of side effects of the drugs including, but not
limited to, direct myocyte injury, activation of apoptotic
and necrotic changes, alternation of ion homeostasis or
the signaling pathways or influence on the transcription
factors i.e. kinase inhibitors [4, 5]. Though, proarrhythmia
represents one of the most frequent cardiac safety liabil-
ities responsible for cardiotoxic effect especially in the late
stage of clinical development and during post-marketing
surveillance [6]. The most important drug-induced form
of proarrhythmia is acquired long QT syndrome (LQTS)
and resulting potentially fatal polymorphic ventricular
tachycardia termed torsades de pointes (TdP).
Tremendous progress has been made in research on
and understanding of mechanisms underlying QT pro-
longation and TdP risk since the 1920s when quinidine
syncope was first recognized. Quinidine was introduced
to the practice as an antiarrhythmic for patients with
atrial fibrillation [7]. Soon thereafter reports of sudden,
occasionally fatal syncopal episodes occurring within
therapy initiation period began to appear. It was not until
the advent of online electrocardiographic monitoring that
the ventricular tachyarrhythmia was described as the
cause of “quinidine syncope” phenomenon in 1964 by
Seltzer and Wray [8]. Characteristic for quinidine poly-
morphic arrhythmia was later observed by Dessertenne in
a patient with atrio-ventricular block [9]. To describe his
observations, twisting QRS complex around the isoelectric
line on the surface ECG, he coined the term “torsades de
pointes”. Interestingly, both of these early reports neither
highlighted nor commented on prolonged QT interval,
which was then observed in patients who were reported in
the late 1970s to have developed TdP. Since that time
much effort has been invested in elucidation of mechan-
ism of drug-induced TdP and despite some reservations
QT prolongation is currently recognized as an underlying
cause of development of the TdP arrhythmia and thus
major focus of drug development and a significant con-
cern for regulatory agencies [10]. It is well known that QT
prolongation is not directly correlated with TdP occur-
rence and ventricular fibrillation. Regardless of the reser-
vations to the predictability of this marker and growing
awareness of its imperfection, QT interval prolongation is
still most commonly used in vivo surrogate of the proar-
rhythmic potency of drugs (ICH E14 guidelines). Pro-
longation of the repolarization process, reflected by long
QT in ECG, can result from a net reduction in the out-
ward current due to either decreased outward potassium
currents (IKr or IKs), or activation of a delayed sodium
current, or an increased inward calcium current [11–14].
However, most cases of prolonged repolarization related
to drug exposure can be traced to the inhibition of hERG
(human ether-a-go-go-related gene) potassium channel
regulating major repolarizing current in the heart, IKr
[15–17]. Therefore during non-clinical phase of drug
development the concentration of the tested substance
producing half-maximal block of the hERG potassium
current (IC50) is an in vitro surrogate for proarrhythmic
propensity of a compound. The class III antiarrhythmics,
for which hERG inhibition underlie in part therapeutic
mechanism of action, are found to carry the highest risk
of TdP, estimated incidence in general population of 5 %
[18]. Yet, inherent property of hERG channel is the ability
to bind and interact with diverse chemical structures that
encompass several therapeutic classes, including, apart
from antiarrhythmics, antibiotics, prokinetics, antipsy-
chotics and antihistamines [19, 20]. The TdP risk for
non-cardiac drugs is generally estimated to be in the
range of < 0.01 % up to 0.1 %, however in patients
certain drugs e.g. dofetilide (anthiarrhythmic) in high
doses it can be as high as 10.5 % [21]. Moreover, most
of these drugs which are used for the symptomatic
treatment of rather benign conditions, are more fre-
quently prescribed with hardly any ECG monitoring
[22, 23]. Upon the results of the survey conducted by
De Ponti et al. it is estimated that up to 3 % of patients
in the UK and Italy are prescribed at least one non-
cardiac drug with proarrhythmic propensity supported
by published data and official warnings about QT pro-
longation or TdP occurrence [24]. Estimates made by
Curtis and colleagues [25] are even higher. Authors
conducted retrospective study and analyzed QT-prolonging
drugs prescribed with the use of outpatient prescription
claims database of the largest pharmaceutical benefit in the
United States and concluded that over 1 million out of
about 5 million patients cohort use at least 1 QT prolong-
ing medication (~23 % of patients). This can explain a great
deal of attention and significant efforts put into the under-
standing, detailed screening and governing of the potential
proarrhythmic potency of novel drugs by the regulatory
(ICH S7 and ICH E14 guidelines), academia and industry
worldwide (ICH S7 E14 guidelines).
Additionally, the problem of acquired QT prolongation
and TdP is further complicated in patients undergoing
polytherapy. Since polypharmacy is a common practice in
clinical settings, it can be anticipated that there is a rela-
tively high risk that a patient will receive at least two drugs
mutually modifying their proarrhythmic potential and
resulting in clinical symptoms or mitigating symptoms con-
nected with one of them [22, 26–29]. In the study by Curtis
and colleagues in a cohort of 1.1 million patients the con-
comitant use of 2 QT prolonging agents was identified in
9.4 % of patients, and the use of ≥3 agents in 0.7 % of
patients. Indeed, clinical cases of TdP are frequently related
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to polypharmacy and drug-drug interaction resulting in QT
interval prolongation [25] The results of retrospective
analysis of FDA AERS (Food and Drug Administration
Adverse Event Reporting System) database by Shaffer et al.,
where concomitant risk factors for QT prolongation and
TdP occurring in association with administration of macro-
lide antimicrobials were examined, pointed out that co-
administration of drug prolonging QT interval accounts for
50 % of registered TdP reports [30].
In populations receiving multiple medications potential
drug-drug interactions (DDIs) are of major concern, there-
fore the topic has received much attention and some formal
approaches have been established. However, they concern
only pharmacokinetic (PK) interactions occurring due to
alterations in drug metabolism or disposition, while assess-
ment of pharmacodynamic (PD) interactions is hardly pos-
sible due to character of the effects of such endpoints
which are serious adverse effects rather than measurable
changes in drug concentration [31]. Although the incidence
of clinically significant PD interactions is much lower than
that of PK interactions, they should not be underestimated
since they can be of great importance for patient safety
[32]. In case of TdP arrhythmia QT interval prolongation
can be used as a relatively safe indicator of PD drug inter-
action result, though a number of drug combinations pos-
sibly implicated in QT prolongation is practically infinite
and it is infeasible to comprehensively assess all of them
during the drug development process and clinical trials.
Additionally significant diversity in the study design, clinical
endpoints analysis, studied populations and other factors
make the PD component of DDIs challenging to analyze.
Terfenadine can be used as an example due to multiple
available studies clearly showing wide range of clinical end-
points, in this case QT prolongation. Figure 1 presents
results of five studies where terfenadine was given either
alone or concomitantly with different CYP 3A4 inhibitors.
One can note obvious QT prolongation which on one hand
side proves the role of DDI, yet at the same time significant
variability in the effect for both scenarios (with and without
inhibitor) can be also seen.
The aim of the study
This publication provides an overview of published clinical
studies results on pharmacokinetic and/or pharmacody-
namic drug-drug interactions in humans (either healthy
volunteers or patients) and their electrophysiological conse-
quences manifested as change in the QT/QTc interval. The
main aim was to present the role and potential clinical rele-
vance of drug combinations for cardiac safety as evidenced
in clinical trials. We aimed in presenting of the diversity of
parameters influencing the electrophysiological effects of
drug combinations in clinic situations; the specific statistical
analysis was neither planned nor conducted.
Methods
Databases of PubMed and Scopus were searched
through November 2014 without time limit. Combina-
tions of the following keywords were used for Title, Ab-
stract and Keywords fields: interaction, coadministration,
combination, DDI and electrocardiographic, QTc inter-
val, ECG. Only human studies were included. Over 4500
publications were retrieved and underwent preliminary
assessment to identify papers accordant with the topic of
this review. Inclusion criteria met only articles describ-
ing clinical studies where the effects of two or more
agents given concomitantly on the QT interval length
were analyzed. All case study reports were excluded
from the analysis. Reference lists from the eligible papers
were the additional source of publications included in
this review. Studies on combinations of antiarrhythmic
drugs where their effect on QT interval was not of
primary concern, and pharmacokinetics of involved
compounds was out of their scope, were considered as
not eligible for this review. Finally, we found 76 publica-
tions to be eligible for this review. They were divided
into several groups, primarily according to the com-
pound defined as victim drug in a clinical trial.
The results of the presented literature review are divided
into two parts: 1) general description of drug classes studied
for the effects of their combinations with metabolic inhibi-
tors or other agents which might be given concomitantly;
and 2) tabularized description of studies protocols, partici-
pants, PK and/or PD changes. The latter is provided as the
Additional file 1: Table S1.
Results
Antiarrhythmics
Antiarrhythmics were the first drugs associated with QT
interval prolongation and ventricular arrhythmia with
the quinidine being most frequently implicated with the
estimated TdP incidence in patients treated ranging
from 1 to 8.8 % or even 28 % in certain groups [18].
Treatment of disorders of cardiac rhythm often requires
polytherapy with antiarrhythmic drugs, many of which
undergo cytochrome CYP450 metabolism. They may be
inhibitors or inducers of CYP enzymes. For this reason
PK and PD interactions between antiarrhythmic com-
pounds can be of clinical importance in terms of
efficacy and toxicity, especially for compounds with
narrow therapeutic range, e.g. quinidine, digoxin, fle-
cainide. Several studies involving antiarrhythmic drugs
had been identified. Their results indicate that multi-
drug regimens may improve treatment efficacy and
safety if chosen properly. On the other hand, they
point out the fact that knowledge of existing and
plausible drug interactions is essential to optimize
therapy for individual patients.
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Twelve published reports from clinical trials were iden-
tified for antiarrhythmic drugs. Tartini and Kappenberger
described excessive prolongation of QT interval and
development of torsades de pointes arrhythmia in two
patients treated with a combination of quinidine and ami-
odarone for minor arrhythmia [33]. The interaction was
confirmed in a 33-year-old male healthy volunteer. Amio-
darone caused significant elevation of quinidine concen-
tration (90 % increase of Cmax) which led to substantial
(41 % as compared to baseline) prolongation of QT inter-
val [34]. The need for careful ECG and quinidine concen-
trations monitoring was concluded. On the contrary,
subsequent administration of verapamil may have a pro-
tective effect against quinidine-related TdP arrhythmia. In
the study described by Theisen and Scheininger [35]
verapamil i.v. was shown to slightly (10 ms) but signifi-
cantly shorten prolonged QTc interval supervene as a
result of quinidine i.v. administration without lowering
quinidine efficacy in a slowing flutter rate and conversion
of atrial fibrillation. In most studies considering quinidine
interactions it was used rather as a perpetrator than victim
drug and possible victim drug toxicity or lack of its effect-
iveness were of primary concern instead of quinidine
cardiotoxicity. In the study aimed at determining whether
calcium antagonists interact with digoxin and influence its
glycoside effects, quinidine (250 mg t.i.d.) induced sub-
stantial increase (118 %) in digoxin concentration [36].
The above resulted in intensification of digoxin glycoside
effects and attenuation of its QTc shortening effect. Other
compounds tested, namely verapamil, gallopamil, propafe-
none and nifedipine, amplified digoxin concentration to a
lesser extent (16-77 %) and further shortened QTc inter-
val. Two further studies investigated a role of quinidine, as
a potent inhibitor of the genetically-determined debriso-
quine 4-hydroxylation (CYP 2D6), in the interactions with
propafenone and propranolole [37, 38].
Both studies showed significant elevations of victim
drugs concentrations: propafenone mean steady-state
plasma concentration increased by 169 % in a group of
extensive metabolizers (no change in 2 poor metabolizing
subjects) and propranolol AUC (area under the plasma
drug concentration-time curve) by 92 %, moreover, the ef-
fect was stereoselective. In Funck-Brentano study despite
changes in propafenone plasma concentration induced by
low dose of quinidine (50 mg) electrophysiological param-
eters remained unaltered. The same dose of quinidine
administered with propranolole resulted in QTc interval
prolongation (up to 29 ms) which may be of therapeutic
importance. However, explanation for this was unclear
since neither propranolole nor quinidine produced delay
of repolarization process when given alone. Changes in
quinidine or its metabolites (not studied) and effects of
propranolole and its metabolites on ventricular repolariza-
tion are among suggested explanations.
Fig. 1 Results of five clinical studies with terfenadine given either alone or concomitantly with different CYP 3A4 inhibitors
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Increased arrhythmia risk is also reported to be related
to high concentrations of flecainide, metabolized by the
cytochrome P450 2D6 izoenzyme antiarrhythmic agent
with relatively narrow therapeutic range. This gave an
incentive for a study of flecainide interaction with amio-
darone, a weak inhibitor of cytochrome CYP 2D6 among
healthy volunteers with polymorphism of CYP 2D6
[39–41]. The study in healthy Caucasian population by
Funck-Brentano et al. failed to find significant differ-
ences between flecainide concentrations in both CYP
2D6 phenotypes (poor and extensive metabolizers).
Significant ECG changes were observed at flecainide
dosage of 100 mg b.i.d. but not at dosage of 50 mg
b.i.d., the extent of changes was similar in both pheno-
types. Combination with amiodarone resulted in signifi-
cant increase in flecainide plasma concentration and
more pronounced QTcF (Fridericia's correction) change
in both, extensive and poor metabolizers. Similarly to ad-
ministration of flecainide alone, the extent of QTcF inter-
val prolongation did not differ significantly between the
groups. Dosage adjustment for flecainide was suggested if
amiodarone is to be co-administered. These results differ
from those reported for population of diseased infants,
where both effectiveness and safety of combined flecainide
and amiodarone in refractory tachyarrhythmias were dem-
onstrated [42]. Fenrich and colleagues declare concord-
ance of their findings with other studies conducted in
adult patients with supraventricular and ventricular tachy-
cardia. Similarly to Funck-Brentano study, Lim et al. did
not find any significant differences in flecainide Cmax at
both occasions, namely administration of flecainide alone
or in combination with paroxetine, between study groups
of healthy Korean male subjects genetically determined as
extensive (EM), intermediate (IM), and poor metabolizers
(PM) [41]. QTc intervals at baseline were comparable in
all 3 groups, significant increases from time-matched
baseline in the QTc intervals were found in all genotype
groups following flecainide administration. The extent of
additional QTc prolongation, when paroxetine was added,
was similar (about 6 ms) and statistically significant in EM
and IM subjects. QTc prolongation in PM was less pro-
nounced (3.9 ms). Quantitatively QTc changes in study
groups did not correspond with AUC changes, and large
interindividual pharmacodynamic variability is suggested
as an explanation of this situation. Authors conclude that
plasma flecainide concentration determination may be an
insufficient predictor of electrophysiologic changes [40].
Another antiarrhythmic drug which can be used in
combinations and tested for its electrophysiological conse-
quences was tedisamil. Tedisamil, as a bradycardic agent
can be used in patients with angina pectoris either alone or
in combination with other anti-anginal drugs thus Demolis
et al. designed and conducted a study aiming in evaluation
of its effects on heart rate and QT interval duration either
alone or in combination with atenolol [43]. Tedisamil, but
not atenolol, prolonged QT intervals in study subjects.
Observed prolongation was reverse rate-dependent as QT
prolongation was much less pronounced at high rather
than at low heart rates. This correlation remained un-
changed during combined therapy with atenolol.
Moreover, since the extent of QT prolongation during
concomitant administration of atenolol and tedisamil
was similar to those observed in monotherapy the
authors state that there is no additional risk arising
from the combination of atenolol and tedisamil.
Quinidine, a class IA antiarrhythmic agent was also
tested in combination used in the therapy of condition
not related with heart rhythm disorders. In the therapy
of pseudobulbar affect (PBA) dextromethorphan is co-
administered with low quinidine doses. While quinidine
doses are of orders of magnitude lower than those for
arrhythmia treatment, 20-30 mg vs 800-2400 mg [44],
the related risk of QT interval should be negligible,
however, during clinical trials investigating efficacy of
dextromethorphan-quinidine combination in PBA
[45–48] patients were monitored for electrophysio-
logical abnormalities. The results proved the assump-
tion on safety of low-dose quinidine therapy.
Antihistamines
Terfenadine and astemizole were the first second-gen-
eration, non-sedating antihistamines. When launched to
the market they were considered as a great breakthrough in
the allergy pharmacotherapy. However, enthusiasm for
them was hampered soon after by the case reports on tor-
sades de pointes [49–52]. A growing number of alarming
reports on terfenadine-related QT prolongations and TdP
cases prompted the FDA to ask its manufacturer to with-
draw the drug due to concerns about potential of the
cardiac arrhythmias and patients sudden deaths, especially
because a new, safer alternative - fexofenadine was ap-
proved. About a year later Johnson & Johnson volun-
tarily withdrew astemizole from the global market.
The data from both astemizole and terfenadine adverse
event reports submitted via the FDA AERS allowed to con-
clude that ventricular arrhythmia was associated with sub-
stantially elevated plasma concentrations of these drugs,
resulting from the drug-drug interactions preventing its
metabolic degradation, hepatic impairment, or overdose
[53, 54]. This urged clinical studies that were about to test
the hypothesis on the role of metabolic inhibition and phar-
macokinetic changes in a QT interval prolongation follow-
ing astemizole and terfenadine administration.
Honig and colleagues published a series of papers
upon their research investigating terfenadine interaction
with well-known inhibitors of hepatic oxidative me-
tabolism, namely erythromycin, clarithromycin and
ketoconazole, which may be co-administered [55–57].
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They also conducted a study for a new at that time
antifungal agents: itraconazole and fluconazole, which
both demonstrate weaker in vitro inhibition of CYP
enzymes than ketoconazole [34, 58], in order to inves-
tigate the magnitude of probably less pronounced but
still plausible interaction [59, 60]. The aim of all the
studies was to examine the influence of DDIs on terfe-
nadine PK and its pharmacodynamic consequences
represented by electrocardiographic changes. Six to
nine healthy subjects, both female and male, were
enrolled for each particular study. During terfenadine
monotherapy (first study phase), only some individuals
had detectable terfenadine concentrations (limit of
quantification in plasma, LoQ – 5 ng/mL), while
inhibitor was added, levels of unmetabolized terfena-
dine increased above LoQ depending on its CYP 3A4
blocking potency. Accordingly, fluconazole (moderate
inhibitor) and azithromycin (weak inhibitor) did not
cause any significant PK changes nor accumulation of
the unmetabolized terfenadine. The results for azithromy-
cin were confirmed by Harris and colleagues in 1995 [61].
In this study none of the subjects had detectable
(>10 ng/mL) terfenadine plasma level throughout the
whole study period. Two further studies investigated
terfenadine DDI with fluoxetine and paroxetine [62, 63].
In all the studies after administration of terfenadine the
QTc interval was prolonged on average by 1 to 18 ms as
compared to baseline. As a consequence of changed ex-
posure, mean QTc increased from 1 to 82 ms (azithromy-
cin and ketoconazole) across the studies.
Another study investigated terfenadine interaction with
an antidepressant nefazodone [64], which has been shown
to selectively inhibit cytochrome CYP 3A4 enzymes in
clinical doses [65]. Terfenadine Cmax and AUC were
markedly increased with concomitant administration of
nefazodone. As expected, interaction resulted in the
significant QTc intervals prolongation when compared to
baseline. Two further studies investigated the PD compo-
nent of interaction with terfenadine [66, 67]. They both
involved sparfloxacin, a broad-spectrum fluoroquinolone
antibiotic pre-clinically and clinically shown to cause
dose-dependent QT interval prolongation. In a group of
healthy men volunteers pharmacokinetics of sparfloxacin
remained unchanged after addition of terfenadine during
study by Morganroth et al. [66]. Akhtar and colleagues did
not investigate PK either for terfenadine or for sparfloxa-
cin [67]. There was no significant increase in the QTc
duration in the terfenadine-treated subjects in both
studies. A combination therapy was found to be con-
nected with additive effect of concomitantly adminis-
tered drugs on the QTc length.
A significant interindividual variability in ECG response
to altered parent terfenadine concentrations was demon-
strated in all of the above presented studies, suggesting a
large role of physiological and genetic factors accounting
for individual susceptibility to a QT prolongation and
cardiac arrhythmia occurrence. Furthermore, substantial
variability of inhibitor effect on terfenadine concentrations
was observed in all studies. This may be due to the differ-
ences between subjects affecting bioavailability of the
drugs or genetically determined diverse levels of CYP450
3A4 expression as well as different CYP inhibitory poten-
cies of ketoconazole, itraconazole and erythromycin. It
has been suggested that function of P-gp or OATP trans-
porters altered by concomitantly administered drugs may
influence the disposition of victim drugs, however, an
interindividual variation in drug transporter expression
further complicates predictions of the interaction effects
in a population [68–71].
Also a single report on the effects of co-administration
of terfenadine metabolite (fexofenadine) with azithromycin
was found [72]. As opposed to results of terfenadine-
azithromycin study, in this study co-administration of
both drugs in a population of healthy volunteers resulted
in substantial increase of fexofenadine bioavailability, how-
ever, it did not lead to any statistically significant or clinic-
ally relevant changes in ECG (QTc interval prolonged by
1.4 ms).
Astemizole interactions were investigated in two studies
[73, 74]. Itraconazole, unlike dirithromycine, significantly
increased astemizole systemic exposure. However, a QT
interval change was not observed in any of the studies.
Nevertheless, authors strongly suggest avoidance of con-
comitant administration of astemizole and itraconazole
because of possible differences between single dose study
results and chronic astemizole intake and anticipated
effect of observed in the Lefebvre study astemizole clear-
ance reduction for prolonged astemizole therapy [74].
Also Bachmann advised further investigation of electro-
physiological consequences for astemizole interaction pro-
posing study with different design, however, since Johnson
& Johnson withdrew astemizole from the market two
years after Lefebvre and Bachmann studies, and according
to our best knowledge, no additional investigations with
publicly available results were carried out [73].
The awareness that the cardiotoxicity is not a class
effect of antihistamines, yet their administration can in-
duce the QT prolongation and in certain circumstances
be potentially proarrhythmic prompted further studies
aimed at assessment of individualized risk for some anti-
histaminic compounds. One of the drugs extensively
studied for its interactions and their electrocardiographic
effects is loratadine with its active metabolite desloratadine.
Four papers reporting five clinical trials with loratadine
administered concomitantly with CYP enzymes inhibitors
having different inhibitory profiles were identified [75–78].
The influence of potent CYP 3A4 (clarithromycin, ketoco-
nazole, nefazodone), moderate CYP 3A4 (erythromycin),
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and weak CYP 3A4 and 2D6 (cimetidine) inhibitors,
according to the FDA classification [34], on loratadine PK
had been studied. The data from those studies demon-
strated anticipated effects of applied inhibitors on the clear-
ance of both loratadine and desloratadine. Despite the
observed differences between magnitude of the pharmaco-
kinetic interactions of loratadine with diverse CYP inhibi-
tors the pharmacodynamic consequences were principally
the same. The tested drug combinations were safe and well
tolerated. The mean QTc interval changes for drug combi-
nations were not significantly different from the increase
accompanying co-administration of inhibitors with placebo.
The results of majority of studies suggest that loratadine
does not share the proarrhythmic potential of other nonse-
dating antihistamines, in particular terfenadine, and consid-
ering the wide safety margin of loratadine its interactions
with CYP inhibitors are probably clinically unimportant.
Safety profile of desloratadine, a major metabolic deriva-
tive of loratadine, has been confirmed in three independent
clinical studies with both recommended clinical and
supratherapeutic dose in healthy volunteers [72, 79–82]. It
was demonstrated that despite induced by ketoconazole,
erythromycin, and azithromycin, higher desloratadine
exposure, the co-medications were well tolerated and
caused neither significant QTc interval prolongation nor
changes in adverse events profile. The authors unanimously
concluded that desloratadine combinations with CYP
inhibitors are safe and may be administered to the patients
without concerns about clinically significant cardiac events.
Tyl and colleagues report on results of the ICH E14
guideline compliant thorough QT/QTc study for a bilastine
[83]. It was shown that bilastine at therapeutic and
supratherapeutic doses don’t have any impact on QTc in-
tervals measured in healthy volunteers. Co-administration
with ketoconazole resulted in an increased bilastine bio-
availability and resulted in increased systemic exposure.
Clinically significant increase in QTc intervals duration was
observed, however, this was most likely related to ketocona-
zole effect alone, as bilastine concentrations did not exceed
those during supratherapeutic doses administration and no
correlation between bilastine PK and QTc was found.
The results of studies concerning antiallergics show that
the actual QT prolongation differs substantially between
individuals, and is dependent not only on hERG inhibition
potential of the agent and metabolic interactions resulting
from polytherapy but also other stages of ADME process
can significantly influence proarrhythmia risk.
Gastrointestinal prokinetic agents
Cisapride, a gastric pro-motility agent indicated for
gastro-oesophageal reflux disease treatment, is another,
after terfenadine and astemizole, hallmark example of
market withdrawal of non-cardiac blockbuster drug due
to unacceptable risk of a QT interval prolongation and
TdP arrhythmia. Cisapride was removed from the global
market [84] as a consequence of several case reports of
major cardiac toxicity, following analysis of the FDA
AERS database by Wysowski et al. 2001 [85] and a case-
control study [86] which provided evidence that cisa-
pride is associated with the increased occurrence of the
QT prolongation, ventricular arrhythmia and sudden
cardiac death. It is worth noted that apart from the drug
related characteristics Wysowski noticed the role of
other factors influencing cisapride clinical effect, includ-
ing but not limited to certain health conditions (i.e. heart
diseases, electrolytes disorder). However, in spite of its
withdrawal, cisapride is still available in the U.S. through
an investigational program to patients who meet certain
criteria since it is considered to be the most effective
agent for gastric motility, as well as in some European
countries. Administration of cisapride alone is known to
be a cause of the QT prolongation [87–90]. However,
many of the adverse reactions ascribed to cisapride
occurred in patients with conditions that could predis-
pose to cardiac arrhythmias or taking other drugs that
inhibit cisapride metabolism via CYP 3A4 enzymes or
prolong QT interval [91]. The increased risk following
metabolic inhibition and co-administration of other QT-
prolonging drug was demonstrated by van Haarst [92]
and Zix [93]. Interestingly, concomitant therapy with
clarithromycin caused substantially greater change in the
QTc interval duration than would be expected from
simple additive effect of both drugs. Due to hERG block-
ing properties of both drugs [94] it was conceivable that
PD interactions may occur with this combination. None-
theless, van Haarst study design did not allow for quanti-
tative assessment of PK and PD component contribution
in this interaction, but dependence of the QTc intervals
on cisapride concentration was observed what suggests an
overriding role of PK component in the overall electro-
physiological effect. The second study investigated the
clinical relevance of possible cisapride interaction with
QT-prolonging drug - sparfloxacin. Considering that, as it
was proven in the study, cisapride has no influence on
sparfloxacin PK and assuming that there is no influence of
sparfloxacin on cisapride PK, the observed QTc prolonga-
tion can be ascribed to PD interaction only. Nevertheless,
reported results do not allow to assess whether the type of
the interaction is additive or synergistic.
Cisapride has narrow therapeutic index thus even weak
inhibition of CYP mediated metabolism and consequent
modest concentration increase is potentially important.
As depression and gastroesophageal reflux disease often
occur together and many of SSRI (selective serotonin re-
uptake inhibitors) demonstrate some extent of CYP in-
hibitory properties, it is important to determine whether
potentially harmful interactions occur between antidepres-
sants and cisapride. In the two identified studies fluoxetine
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[95] and sertraline [96] were studied for effects of their
interaction with cisapride. Data from both studies indicate
that cisapride can be safely administered to patients who
are treated with fluoxetine and sertraline while neither
fluoxetine nor cisapride, nor sertraline, nor their combin-
ation induced statistically or clinically significant ECG
parameters change. This was due to decreased cisapride
concentrations caused by both drugs. For sertraline the
above is in accordance with the results of studies conclud-
ing that it is a weak inducer of CYP enzymes [97, 98],
however for fluoxetine reasons for such an effect are un-
clear, while fluoxetine with its active metabolite, norfluox-
etine, are inhibitors of CYP P450 system enzymes [99].
Two newer, more selective (as compared to cisapride)
5-HT4 receptor agonists were studied for their cardiac
safety under conditions known to favor arrhythmia
development with cisapride, namely CYP mediated me-
tabolism inhibition [27, 100, 101]. The results of both
studies indicate that neither mosapride nor cinitapride
itself carry proarrhythmic potential since they did not
produce any changes in the electrocardiograms. Also,
there was no significant correlation between plasma con-
centrations of both drugs and QTc intervals. Moreover,
concomitant administration with potent CYP inhibitors,
ketoconazole and erythromycin, resulted in only slight
increases in plasma concentrations of victim drugs,
though without any clinically significant changes in elec-
trocardiographic findings.
Boyce and colleagues designed a study to assess the
PK and electrophysiological effects of domperidone and
ketoconazole, an agent influencing domperidone metabol-
ism and P-gp dependent disposition, and the consequences
of their interaction in healthy volunteers [26]. Ketoconazole
significantly increased domperidone plasma concentrations
in all subjects, however observed PD effects were strongly
dependent on gender, and were more pronounced in men,
for both compounds given alone and their combination.
Based on the results the authors conclude that domper-
idone and ketoconazole should not be administered
concomitantly.
Antiemetics
Droperidol (dopamine D2 receptor antagonist) and
ondansetron (serotonine 5-HT3 receptor antagonist) are
the first-line antiemetics for prevention and treatment
of postoperative nausea and vomiting (PONV). Both
drugs have shown effectiveness in monotherapy, how-
ever, there is evidence that patients at high risk of emesis
can benefit from their combination [102, 103]. Since
both droperidol and ondansetron are known to prolong
QT interval, it can be anticipated that the clinical effect
of combined therapy may be modified by drug interac-
tions and result in the increased risk of proarrhythmia.
Two studies considering the effects of droperidol and
ondansetron (alone and in combination) on QT inter-
val duration have been identified [104, 105]. Both
studies led to conclusion that arrhythmia risk for drug
combination is not higher when compared with both
antiemetics administered alone.
Ondansetron electrophysiological safety was also studied
in combination with sevoflurane [106].
The results of this study indicated that despite of
significant QTc prolongation by sevoflurane and enhance-
ment of this effect by ondansetron the dispersion of ven-
tricular repolarization is not affected and drug combination
may be clinically safe. However, an additional risk factors
assessment before administration and careful ECG moni-
toring was advised.
QT prolongations precipitated by droperidol and “black-
box” warning issued by FDA on possible ventricular ar-
rhythmias associated with droperidol administration led to
reduction of its use and search for compound sharing its
antiemetic activity but with better safety profile. Two of the
considered droperidol substitutes, found to have an effect
on PONV (haloperidol and midazolam), were assessed for
efficacy and safety in combination with dexamethasone. No
significant QTc changes were found while the incidence of
PONV was reduced [107, 108].
Psychotropic drugs
Polypharmacy involving psychotropic drug combinations
is common despite the lack of evidence of its efficacy
and safety [109]. The electrophysiological effects of psy-
chotropic drugs used in monotherapy have been studied
extensively, however the influence of combined therapy
on QTc was not as widely investigated.
In the retrospective study, Correl and colleagues investi-
gated the risk of QTc prolongation for patients on mono-
and polytherapy with antipsychotics [110]. Patients treated
concurrently with two atypical antipsychotics were matched
with controls on monotherapy for sex and antipsychotic
agent. The average QTc dispersion observed in combin-
ation therapy group was similar among patients treated
with monotherapy, despite the fact that patients receiving
antipsychotic polytherapy were administered significantly
higher chlorpromazine-equivalent dosages. These results
suggest that polytherapy with two atypical antipsychotics,
in moderate doses, does not involve significant QTc pro-
longation and challenge the common assumption about
dose-dependence of QTc prolongation for antipsychotics
[111, 112]. Similarly, Sala with coworkers in their retro-
spective study did not find any significant increase in the
average QTc interval following antipsychotic monotherapy
(haloperidol, olanzapine, risperidone or clozapine) in female
patients. There was, however, meaningful QTc prolongation
noted when antidepressants (escitalopram, citalopram, mir-
tazapine, paroxetine, sertraline, fluvoxamine, venlafaxine,
clomipramine) or lithium were administered concomitantly
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[113]. The average QTc interval and QTc change after
treatment was 421 ± 20 ms and -1 ms in the monotherapy
group and 438 ± 30 ms and 24 ms in the polytherapy group.
Moreover, there was a significant difference between the
treatment groups in the number of patients who had QTc
values above 450 ms, seven patients (38 %) in the polyther-
apy group vs. one patient (7 %) in the monotherapy.
Antidepressant agents investigated in the study are known
to have a mild inhibitory activity on drug-metabolizing
enzymes from CYP family, however, in this study PK inter-
actions did not seem to contribute substantially to QTc
prolongation in the group with combined therapy as serum
levels of antipsychotics were not higher in this group com-
pared to monotherapy patients. In the view of the results
authors suggest an accurate monitoring of the QTc before
and after the treatment, especially for those receiving mul-
tiple psychoactive agents with QT prolonging propensity.
Some of the drug combinations analyzed in poly- and
monotherapy were also investigated more thoroughly in
other studies [96, 114–117]. Drug pairs studied included
other psychoactive agents commonly used together with
antipsychotics and with metabolic inhibitors, administra-
tion of which is likely to coincide with psychoactive com-
pounds (itraconazole, ketoconazole, clarithromycin). The
studied DDIs did not result in as dramatic changes of PK
and PD as in case of terfenadine and ketoconazole, yet
complex and individualized risk to benefit ratio evaluation
is advised prior to prescription of any antipsychotic.
Agents used in drug dependence therapy
Racemic methadone is used in maintenance therapy of opi-
ate addicts. Both S- and R-form of methadone inhibit the
cardiac potassium channel hERG (S-methadone is more
potent blocker) [118], which may increase heart risk.
Indeed, the incidences of torsades de pointes arrhythmia in
methadone-treated patients have been reported [119].
Drugs tested for potential increase in the cardiac risk of
methadone include voriconazole, which can be adminis-
tered concomitantly in case of serious fungal infections
occurring in addicts [120]. Administration of lofexidine, an
agent used inter alia for opioid detoxification, may coincide
with methadone as it supports transition from methadone
to buprenorphine [119]. No significant changes in QTc
length were observed neither in patients receiving only
methadone nor in patients on drug combination.
Another agent used in opioid dependence treatment is
buprenorphine, which can be also given concomitantly
with naloxone [121, 122]. Although buprenorphine is
said to inhibit IKr potassium current only in concentra-
tions higher than therapeutic, being CYP 3A4 substrate it
is prone to interact and consequently to put patients at
risk of QT interval prolongation. Electrophysiological con-
sequences of CYP 3A4 inhibition induced by antiretrovir-
als with range of inhibitory potential were evaluated and
proved this mechanism to be out of clinical importance in
terms of QTc interval prolongation.
Modafinil is considered as a potential treatment for
cocaine addiction, thus the co-administration of both
compounds to cocaine addicts seemed possible. While
cocaine is said to prolong QT interval and the potential
enhancement of that effect by modafinil is probable, a
study assessing ECG changes in case of concomitant
administration of these agents was designed [123]. In
general, this group of drugs is not associated with
significant QT prolongation risk, even in combinations
with agents which administration likely coincides.
Antimalarials
To date malaria still claims the lives of people in tropical
countries. Chloroquine that used to be antimalarial of
choice is no longer as highly effective as initially [124].
However, it may be still used to potentiate the curative
effect of other drugs. The drugs combinations investigated
for their pro-arrhythmic potential include i.e. primaquine
plus chloroquine, tafenoquine and chloroquine, amo-
diaquine and halofantrine, halofantrine and mefloquine,
atovaquone and proguanil, artesunate and mefloquine,
artemether and lumefantrine, dihydroartemisinin and
dihydroartemisinin/mefloquine combination, dihydroarte-
misinin and piperaquine what gives a flavor of its potential
clinical meaning with regard to the cardiac safety
[125–137]. Despite substantial changes in drugs PK
observed in some of the studies in a majority of cases
there was no correlation between plasma concentra-
tion of drugs and electrophysiological effects and no
clinically important QTc interval prolongation cases
were found. Cardiac safety of antimalarials was also
confirmed in a study by Lefèvre and colleagues [138]
where despite the artemether/lumefantrine pharmaco-
kinetic changes caused by ketoconazole, ECG parame-
ters, including QTc interval, did not exceeded normal
limits in either of treatment groups.
Varia
Several interaction studies focusing on the cardiac safety
of drugs from other therapeutic groups were identified.
They concern anesthetics given concomitantly with anti-
cholinergics [139], neuromuscular blockers and their
antidotes [140, 141], medications used for treatment of
asthma and chronic obstructive pulmonary disease (fluti-
casone furoate/vilanterol) [142], combination of antihy-
pertensive drugs (losartan and spironolactone) [143] and
others [29, 142, 144].
Discussion and conclusions
Fatal in consequences terfenadine – ketoconazole case
with cardiac related deaths played a significant role in
recognition of the clinical role of drug-drug interactions
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and their desirable and undesirable consequences [145].
The pharmacokinetic DDI studies are now part of the
drug screening procedure for multiple reasons which in-
clude, but are not limited to, assessment of necessity of
a dosage adjustment, need for additional therapeutic
monitoring, or due to the safety reasons when certain
drugs should be contraindicated for concomitant use for
the sake of patient safety.
The available guidance focuses on the PK drug inter-
action studies where the blood or tissue concentrations
are modified by the disruption of drug’s absorption, dis-
tribution, metabolism, and excretion processes triggered
by the interacting compounds [146]. It was not assessed
in the current study as it needs separate, specifically
designed analysis but it is not surprising that majority of
the above mentioned drugs are metabolized by CYP 3A4
and CYP 2D6 [147]. It opens the possibility to undergo
the metabolic interaction (inhibition or induction) resulting
in the clinical effect modification. Therefore this can be
considered as a drug related risk factor, similarly to the drug
transporters (e.g. P-gp) affinity, protein binding, high lipo-
philicity and consequent significant heart tissue penetration
[148–150]. Assessment of the pharmacodynamic effects of
the drug interactions is much more challenging due to the
significant diversity in the endpoints which should be
analyzed depending on the clinical effect. Pharmacokinetic
parameters modification including AUC and Cmax are rela-
tively easy to assess as compared with the pharmacody-
namic endpoints for which the clinical surrogates are often
imperfect if they exist at all. Another challenge comes with
the results variability, which results from exposure variabil-
ity and factors specific for the observed parameter, so the
interacting drugs add additional level of complexity to
already complex situation. Analyzing trials’ results for
evaluation of DDIs role in proarrhthmia risk brings
additional hurdles. This is mainly due to the differences
in study design e.g. single dose or multiple dose proto-
col, study duration, population age, sex, or ethnicity
and methods of evaluation of raw data used to generate
reported endpoints. First, there are several methods for
QT interval length correction for heart rate, Bazzet,
Fridericia or individual or population-based, just to
mention those most commonly used, without individual
data it is impossible to compare the results between the
studies [151]. Second, the reported endpoint can be
substantially influenced by the applied method of
comparison. Drug-triggered QTc changes may be re-
ferred to placebo control or to the baseline QT values.
Fig. 2 PK fold change (Cmax) vs. PD fold change (QTc). Fold change = CmaxCombination/CmaxDrug and ΔQTcCombination/ΔQTcDrug; Negative
values of QTc fold change represent QTc interval change for negative ΔQTc values as compared to baseline (QTc shortening for single drug, as
well as for the combination)
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Baseline measurement can be defined as QTc interval
length at single point registration (rarely reported time of a
day) or mean from several time points. Similarly, reported
QTc values were derived in various way, e.g. maximal and/
or average of individual QTc values at defined time point
after drug application, maximal and/or average of individual
QTc values over several hours following last day of drug ap-
plication [152]. Finally, in some cases, reader can be con-
fused about the true value of the reported endpoints, while
there are different values reported in the tables and in the
text or graph. Nevertheless, DDIs’ role was clearly shown in
the retrospective analyses done by multiple authors. Haugaa
and colleagues correlated QT-related mortality with mul-
tiple factors and found that number of QT-prolonging
medications was a significant predictor of death [153].
Similar results were observed in DeBruin study where the
risk of cardiac arrest was more pronounced in patients re-
ceiving more than 1 QT-prolonging drug simultaneously
[154]. The collation of studies identified for this overview
suggest the need for assessment of an additional risk factors
for proarrhythmia as there are examples where pharmaco-
kinetic changes do not contribute substantially to QTc
interval prolongation and plasma concentrations are not
correlated with observed electrophysiological effects (Fig. 2).
Careful ECG monitoring before administration of drug
combinations with anticipated QT prolongation, especially
with concomitant risk factors, has been suggested in many
of the reports. However, there are some concerns on moni-
toring cost effectiveness [155].
Moreover, it can be safely assumed that the list of studies
presented in the current publication covers just small num-
ber of potential combinations and additionally the incidence
of the life threatening situations is low therefore it is quite
likely that clinical trials with their current methodology can-
not offer the expected power. Also, in case of elderly, multi-
morbid, or critically ill patients undergoing polytherapy the
DDI risk is substantially increased, while such scenario test-
ing is barely feasible, if not impossible at all and can be only
analyzed retrospectively [156]. One of the possible ways of
thorough data analysis is a traditional “top-down” PK/PD
modeling and simulation (M&S). In such approach empir-
ical or descriptive models are utilized to describe the linkage
between drug concentration and observed clinical response
including cardiovascular biomarkers [157]. There are
multiple examples of studies utilizing such approach for
DDI assessment [158], although there are just few where
PK/PD type of analysis was utilized for the assessment of
QT modification triggered by the combination of drugs
[159]. There are examples of successful implementation of
nonlinear mixed-effects PK/PD models and Bayesian
methods. Such approach can be especially useful when
there is either limited or noised dataset. Prior distributions
for the model parameters derived from previous single drug
studies can improve predictivity and model quality [160].
It all suggests the need for a system of early prediction of
the potential DDI clinical consequences. To the authors’
best knowledge there is no established in vitro methodology
offering such possibilities therefore potential solution lays
in the proper use of the in silico based methods. This prop-
osition can be supported by the recent wide incorporation
of the in silico realized in vitro – in vivo extrapolation ap-
proach to the assessment of the clinical role of drug – drug
interactions [161, 162]. Recently discussed drug cardiac
safety assessment paradigm change includes wide use
of mathematical models of human heart cells. This fact
allows us to suggest that after proper validation such
methods could be also applied for the fast and cost-
effective DDI consequences assessment which cannot
be done in the traditional way due to the multiple
obstacles.
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